FIGURE

Fig. 5

ID

ZDB-FIG-260322-41

Publication

Nelen et al., 2026 - Targeting replication stress in neuroblastoma by exploiting the synergistic potential of second generation RRM2 and CHK1 inhibitors

Other Figures

All Figure Page

Back to All Figure Page

Fig. 5

Benchmarking gene expression signatures following TAS1553 exposure in combination with either SRA737 or prexasertib.

A Volcano plots of IMR-32 (top) and CLB-GA (bottom) of significantly DEGs after treatment with 0.74 nM prexasertib and 0.88 µM TAS1553 for 48 h. Genes indicated by name cover the top 15 DEGs. NS not significant. B Volcano plots of IMR-32 (top) and CLB-GA (bottom) of significantly DEGs after treatment with 0.28 µM SRA737 and 0.51 µM TAS1553 for 48 h. Genes indicated by name cover the top 15 DEGs. NS= not significant. C Bubble plot showing the top gene sets enriched after the indicated combination treatment for 48 h for IMR-32 and CLB-GA. D GSEA of the RNA-seq based transcriptome profiles following combined drug treatment with TAS1553 and prexasertib (left) or TAS1553 and SRA737 (right) in IMR-32 cells showing a significant overlap between genes enriched upon combination treatment of TAS1553 with prexasertib, TAS1553 with SRA737 or 3-AP with prexasertib. E Heatmap showing the NES scores from our different combination treatments compared to publicly available gene sets [4, 5, 43–45]. F Representative immunoblotting data for MYCN in IMR-32 following 48 h treatment with 0.74 nM prexasertib and 0.88 µM TAS1553 or 0.28 µM SRA737 and 0.51 µM TAS1553. The quantification of all replicates (N = 3) is shown in Supplementary Figure S8B, D.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Cell Death Dis.